The Catalyst

Most Recent Posts

11.01.11 | By Greg Lopes
In a recent blog post in the Washington Post, Sarah Kliff highlights a new effort by the Bipartisan Policy Center to pitch their deficit reduction proposal for price controls in Medicare Part D, claiming that the projected long term costs of Medicare on prescription drugs will outpace spending on hospitals and doctors.
10.31.11 | By Greg Lopes
In case you missed it, Robert Book has an interesting story in Forbes on the President's jobs package and his proposal to impose rebates in Medicare Part D.
10.28.11 | By Kate Connors
This week, I spent a few days at an R&D facility belonging to one of PhRMA's member companies. This isn't the first time I've been able to tour a research lab, but this particular trip provided me with incredibly enlightening face time with many members of the staff there. From vaccines to intellectual property to global security, I had the chance to learn how this company goes about its business - not just from a policy standpoint - like how we at PhRMA tend to focus our attention - but every day.

Biopharmaceutical research companies have long supported efforts like Global Health Progress to identify global health challenges and find solutions.

10.25.11 | By Kate Connors
Previously on The Catalyst, I have written about what the passage of this year's patent reform law, the Leahy-Smith America Invents Act, means to biopharmaceutical research companies. But in the grand scheme of things, we represent just one industry in America that relies on patents (and other forms of intellectual property) as an incentive for the work that we do.
10.20.11 | By Kate Connors

There probably aren't many of us who don't know seniors who get their prescription drug coverage through Medicare Part D. Now that the open enrollment period has begun - and ends early this year, on December 7 - it's helpful to remind those loved ones about the importance of evaluating their current plans to see if their needs are being met. If not, they can find out if there are better options available.

10.19.11 | By Greg Lopes
Yesterday, Medicare Today released the latest Part D satisfaction survey. The results of the survey show that once again enrollees are highly satisfied with the program - this year to the tune of an 88 percent overall satisfaction rate.
10.17.11 | By Kate Connors
Today, I went to the doctor about a sinus infection that I can't seem to kick. As part of our new attack on this virus, he prescribed me an inhaler, then stepped out of the examining room. He returned a moment later with a sample of the inhaler so that I could begin this important treatment regimen as soon as possible.
Sometimes medical progress seems slow and we forget how much progress has really been made over the years.
10.14.11 | By Greg Lopes

We'd like to give you a heads up that tomorrow, October 15, kicks off the 2012 open enrollment period for Medicare Part D. This marks the time when eligible beneficiaries can sign up for Medicare prescription drug coverage - Part D - for the first time or to switch to a plan that better meets their needs. This year the open enrollment period goes through December 7.

10.13.11 | By Jay Taylor, By Jay Taylor
Yesterday, Congress - with an unusually high level of bi-partisan support - passed the Korea-U.S. Free Trade Agreement. PhRMA has supported this effort for a long time and thinks that the transparency, ethical business practices and intellectual property provisions achieved in the agreement represent a good baseline for other agreements now under consideration - such as the Trans-Pacific Partnership.
10.13.11 | By Kate Connors
Former Senator Tom Daschle penned an op-ed in today's Roll Call about how preventing type 2 diabetes can help to control health care costs.
10.12.11 | By Greg Lopes
The Campaign for Modern Medicines (@modernmeds) and Eli Lilly & Company (@LillyPad) would like to invite you to join two separate Tweetchats on Medicare Part D, the prescription drug benefit program. I'm participating and I hope you will too!
10.12.11 | By Kate Connors

Our digital wizards have created another great video, this one about the more than 900 new target="_blank">biologic medicines that are currently in development to treat more than 100 diseases. It features both researchers - including the chief medical officer of Novo Nordisk, Dr.

10.11.11 | By Kate Connors

The Wall Street Journal's Laura Landro wrote today about how patients can benefit from programs that encourage improved adherence to needed medicines.